Tislelizumab in People With Colorectal Cancer
NCT06529523
Recruiting
The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug. All participants in this study will be treatment naïve (they have not yet received treatment for their cancer), and their cancer will be mismatch repair deficient (dMMR). dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process. Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +2 locations
Conditions: Colorectal Cancer
Register for Updates
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509
Recruiting
This study is open to adults who participated in a previous clinical study with brigimadlin. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants are grouped in cohorts depending on their treatment in the previous study: * Cohort 1a got brigimadlin and continues treatment with brigimadlin * Cohort 1b got brigimadlin for 4 or less tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Precision NextGen Oncology, Beverly Hills, California +41 locations
Conditions: Solid Tumours
Register for Updates
Puberty, Testosterone, and Brain Development
NCT06670053
Recruiting
Transmasculine youth (female sex assigned at birth, male gender identity) who begin clinical gender affirming hormone therapy (GAHT) with testosterone (T) may experience changes in headache. Researchers think this because studies published on effects of giving testosterone to cisgender females (female sex, female gender identity) and transmasculine adults seem to show an effect on pain. This research will help us learn more about changes in headache and in brain structure and function in transm... Read More
Gender:
ALL
Ages:
Between 12 years and 20 years
Trial Updated:
04/02/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Gender Identity, Gender Dysphoria in Adolescents and Adults, Headache, Transgender
Register for Updates
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
NCT06710548
Recruiting
The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Ovarian Cancer, Advanced Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Cancer, PARP Inhibitor, Fatigue Related to Cancer Treatment, Fatigue in Cancer Survivors
Register for Updates
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316
Recruiting
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Stanford Cancer Institute, Palo Alto, California +7 locations
Conditions: Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Register for Updates
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262
Recruiting
Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: MarinHealth Spine Institute, Larkspur, California +1 locations
Conditions: Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Register for Updates
A Single-session Intervention Adaptation of the Habit Framework for the Prevention of Eating Disorders
NCT06861608
Recruiting
The purpose of this proposal is to launch the first trial of a single-session intervention (SSI) specifically for the prevention of eating disorders (EDs).
Gender:
ALL
Ages:
Between 18 years and 22 years
Trial Updated:
04/02/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Eating Disorder Not Otherwise Specified
Register for Updates
Drug-Drug Interaction Potential of Mavorixafor
NCT06914869
Recruiting
The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/02/2025
Locations: Parexel International LLC, Baltimore, Maryland
Conditions: Healthy Participants
Register for Updates
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
NCT02843945
Recruiting
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Tampa General Hospital, Tampa, Florida +5 locations
Conditions: Pancreatic Cancer
Register for Updates
Use of Bone Marrow Concentrate for Treatment of Alar, Accessory, and Transverse Ligament Injuries
NCT03517761
Recruiting
The purpose of this study is to evaluate the effectiveness of using anterior approach through the posterior oropharynx for treating alar and transverse ligament injuries with bone marrow concentrate for patients with craniocervical junction (CCJ) instability.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/02/2025
Locations: Ehren Dodson, Broomfield, Colorado
Conditions: Craniocervical Injuries
Register for Updates
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542
Recruiting
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Part 2 is now closed to accrual.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: City of Hope National Medical Center, Duarte, California +53 locations
Conditions: Prostate Cancer
Register for Updates
Telehealth and Memory Study
NCT04586530
Recruiting
The overall purpose of this trial is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction among (female or male) breast cancer survivors. This is a multi-center, multi-clinician randomized control trial (MAAT vs. supportive therapy attention control condition). This trial will also evaluate a sub-sample of survivors pre-and post treatment with functional magnetic resonance imag... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Indiana University, Indianapolis, Indiana +1 locations
Conditions: Chemotherapy-related Cognitive Dysfunction
Register for Updates